Safety evaluation of a multiallergen immunotherapy treatment in polyallergic patients. APOLO observational study
Por:
Alba P, Moreno V, Arias-Irigoyen J, Antón M, Parra A, Gómez-Fernández MC, Madariaga B, Martínez A and Begoña L
Publicada:
1 ene 2020
Ahead of Print:
6 ene 2020
Resumen:
Aim: Assessment of safety, tolerability and changes in global clinical impression with an multiallergen immunotherapy treatment without dilutional effect in polyallergic patients. Patients & methods: This observational prospective study included patients with allergic rhinitis-rhinoconjunctivitis with or without asthma between 5 and 60 years old receiving immunotherapy treatment with a mixture of two allergenic sources. All adverse events were recorded. Global clinical impression, tolerability subjective assessment and satisfaction were also assessed. Results: 130 patients were analyzed. Nine clinically relevant local adverse reactions were reported in six patients (4.6%). Six systemic reactions (grades 0-I) occurred in four patients (3.1%). Patients improved significantly in their global clinical impression. Good tolerability subjective assessment and satisfaction values were also observed. Conclusion: This multiallergen immunotherapy treatment without dilutional effect can be considered as a potential therapeutic alternative for polyallergic patients suffering from allergic rhinitis.
Filiaciones:
Alba P:
Hospital de Manises. Allergy Department, Manises, Valencia, Spain
Moreno V:
Clínica Dra. Victoria Moreno, Huelva, Spain
Arias-Irigoyen J:
Clínica Dr. José Arias Irigoyen, Huelva, Spain
:
Department of Allergy, Hospital Universitario del Vinalopó. Elche, Alicante, Spain
Parra A:
Department of Allergy, Complejo Hospitalario Universitario A Coruña, A Coruña, Spain
Gómez-Fernández MC:
R&D Department, ROXALL Medicina España S.A., Zamudio, Bizkaia, Spain
Madariaga B:
R&D Department, ROXALL Medicina España S.A., Zamudio, Bizkaia, Spain
Martínez A:
R&D Department, ROXALL Medicina España S.A., Zamudio, Bizkaia, Spain
Begoña L:
R&D Department, ROXALL Medicina España S.A., Zamudio, Bizkaia, Spain
|